Heterogeneous contributions of APOBEC3 deaminases to substitution and indel mutagenesis in lung adenocarcinoma.

Authors

Josefine Striepen, Luka Culibrk, Alexandra Dananberg, Jacob S Rozowsky, Mia Petljak, John Maciejowski

Published in

Cell reports. Volume 45. Issue 11. Pages 118215. Oct 26, 2026. Epub Oct 26, 2026.

Abstract

APOBEC3 cytosine deaminases are major sources of cancer mutations. In lung adenocarcinoma (LUAD), APOBEC3 activity drives tumor evolution and therapy resistance, nominating these enzymes as therapeutic targets. Although APOBEC3A drives most APOBEC3-associated mutational signature burden across cancers, the relative contributions of individual paralogs in LUAD remain unclear. Here, we define the roles of endogenously misregulated APOBEC3 deaminases using CRISPR-Cas9 knockouts and whole-genome sequencing of 197 long-term propagated single-cell clones. APOBEC3 mutagenesis falls into three patterns, driven predominantly by APOBEC3A, by both APOBEC3A and APOBEC3B, or minimal despite detectable enzyme expression. Commonly used surrogate measures, including mRNA and protein levels and in vitro deaminase activity, do not predict these contributions. We also provide the first causal evidence that endogenous APOBEC3A generates the indel signature InD9a, linking it to uracil excision following cytosine deamination. These heterogeneous contributions highlight the need for biomarkers that resolve individual APOBEC3 activities to guide therapeutic targeting.

PMID:
42945210
Bibliographic data and abstract were imported from PubMed on 28 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.